Failure to respond (reduction ≥ 50% on HDRS) · patients with depression
Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with tianeptine (moderate certainty).
1 finding from 1 review
Endpoint score (HDRS or MADRS) · patients with depression
1 finding from 1 review
Failure to complete ‐ total ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ total ‐ compared with tianeptine (moderate certainty).
1 finding from 1 review
Failure to complete ‐ inefficacy ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with tianeptine (moderate certainty).
1 finding from 1 review
Endpoint score (HDRS or MADRS) · patients with depression
1 finding from 1 review
Failure to complete ‐ side effects ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ side effects ‐ compared with tianeptine (moderate certainty).
1 finding from 1 review
Failure to respond (reduction ≥ 50% on HDRS) · patients with depression
Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with trazodone (moderate certainty).
1 finding from 1 review
Endpoint score (HDRS or MADRS) · patients with depression
1 finding from 1 review
Failure to complete ‐ total ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ total ‐ compared with trazodone (moderate certainty).
1 finding from 1 review
Failure to complete ‐ inefficacy ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with trazodone (moderate certainty).
1 finding from 1 review
Failure to complete ‐ side effects ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ side effects ‐ compared with trazodone (moderate certainty).
1 finding from 1 review
Failure to respond (reduction ≥ 50% on HDRS) · patients with depression
Fluoxetine probably leads to higher failure to respond (reduction ≥ 50% on HDRS) compared with venlafaxine (moderate certainty).
1 finding from 1 review
Endpoint score (HDRS or MADRS) · patients with depression
1 finding from 1 review
Failure to complete ‐ total ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ total ‐ compared with venlafaxine (moderate certainty).
1 finding from 1 review
Failure to complete ‐ inefficacy ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with venlafaxine (moderate certainty).
1 finding from 1 review
Failure to complete ‐ total ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ total ‐ compared with agomelatine (moderate certainty).
1 finding from 1 review
Failure to complete ‐ side effects ‐ · patients with depression
Fluoxetine probably leads to lower failure to complete ‐ side effects ‐ compared with venlafaxine (moderate certainty).
1 finding from 1 review
Failure to complete ‐ inefficacy ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with agomelatine (moderate certainty).
1 finding from 1 review
Failure to complete ‐ side effects ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ side effects ‐ compared with agomelatine (moderate certainty).
1 finding from 1 review
Failure to respond (reduction ≥ 50% on HDRS) · patients with depression
Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with amineptine (moderate certainty).
1 finding from 1 review